. Author manuscript; available in PMC: 2017 Apr 1.

Published in final edited form as: J Eur Acad Dermatol Venereol. 2015 Dec 10;30(4):645–649. doi: 10.1111/jdv.13478

Table II.

DLQI Median Total Score at Baseline, Week 4, and Week 12, by Treatment Regimen

Assessment period	Single (n = 66)	Monthly (n = 138)	Early (n = 133)	Placebo (n = 67)
Baseline, n (%)	65 (98.5 %)	136 (98.5 %)	132 (99.3 %)	67 (100.0 %)
median (25; 75 percentiles)	10.0 (5.5; 15.0)	11.0 (6.0; 17.5)	11.0 (7.0;16.0)	12.0 (8.0; 17.0)
Week 4, n (%)	64 (97.0 %)	133 (96.4 %)	130 (97.7 %)	65 (97.0 %)
median (25; 75 percentiles)	6.0 (2.0; 11.0)^*	3.0 (3.0; 11.5)^*	5.0 (2.0; 9.0)^*	11.0 (6.0; 18.0)
Week 12, n (%)	62 (93.9 %)	132 (95.7 %)	128 (96.2 %)	58 (86.6 %)
median (25; 75 percentiles)	7.5 (3.0; 11.0)^**	4.5 (1.0; 8.0)^*	3.0 (1.0; 18.0)^*	12.0 (6.0; 19.0)

DLQI = Dermatology Life Quality Index.

P ≤ 0.001 compared with placebo

^**

P = 0.003.